Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Type 1 Diabetes Preclinical Testing Program Resource Report Resource Website |
Type 1 Diabetes Preclinical Testing Program (RRID:SCR_006861) | T1D-PTP, NIDDKT1D-PTP | service resource, resource | THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Investigator access is provided to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics in cases where additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the Type 1 Diabetes Rapid Access to Intervention Development (T1D-RAID) development pipeline. The T1D-RAID program provides resources for pre-clinical development of drugs, natural products, and biologics that will be tested as new therapeutics in type 1 diabetes clinical trials. The T1D-RAID program is not currently accepting applications. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources, to assist in preclinical development of therapeutics for T1D: * Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) (NOT-DK-09-006) * Needs for Preclinical Efficacy Testing of Promising Agents to Prevent or Reverse Diabetic Complications (NOT-DK-09-009) The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain proof of principle establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation. | testing, therapeutic, clinical, drug, preclinical, therapy, drug development, high-throughput screening, animal model, formulation, pharmacology, toxicology |
is related to: Type 1 Diabetes - Rapid Access to Intervention Development is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Diabetes | NIDDK | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152741 | SCR_006861 | Type 1 Diabetes Preclinical Testing Program (T1D-PtP), NIDDKType 1 Diabetes Preclinical Testing Program | 2026-02-12 09:44:25 | 0 | |||||
|
Functional Dyspepsia Treatment Trial Resource Report Resource Website |
Functional Dyspepsia Treatment Trial (RRID:SCR_006691) | FDTT | clinical trial, resource | Multi-center, randomized, placebo-controlled trial evaluating the tricyclic antidepressant, amitriptyline and the selective serotonin reuptake inhibitor (SSRI), escitalopram to placebo in patients with functional dyspepsia. The purpose of this study is to determine whether amitriptyline and escitalopram are more efficacious than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidities. | antidepressant, amitriptyline, selective serotonin reuptake inhibitor, escitalopram, placebo |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: ClinicalTrials.gov |
Functional dyspepsia | NIDDK | PMID:22343090 | nlx_152830 | SCR_006691 | Antidepressant Therapy for Functional Dyspepsia, Functional Dyspepsia Treatment Trial (FDTT) | 2026-02-12 09:44:17 | 0 | |||||
|
Maryland Genetics of Interstitial Cystitis Resource Report Resource Website |
Maryland Genetics of Interstitial Cystitis (RRID:SCR_006992) | MaGIC | clinical trial, resource | Clinical study that investigated several hundred families with two or more blood relatives with interstitial cystitis in order to understand the molecular genetic basis of this condition. The study sought to find changes in genes that are found far more commonly in family members who have interstitial cystitis than in those who do not have the disease. Identifying these genes should lead to a better understanding of the cause of interstitial cystitis. This is a national study which is conducted by telephone and mail, and in which participants could participate entirely from their home. | male, female, adolescent, adult human, genetics, risk factor, family history, bladder, pain, observational |
is related to: NIDDK Information Network (dkNET) has parent organization: ClinicalTrials.gov has parent organization: University of Maryland School of Medicine; Maryland; USA |
Interstitial cystitis | NIDDK | nlx_152843 | http://icresearch.umaryland.edu/magic.aspx | SCR_006992 | Maryland Genetics of Interstitial Cystitis (MaGIC) | 2026-02-12 09:44:21 | 0 | |||||
|
High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis Resource Report Resource Website |
High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (RRID:SCR_006772) | HUSC | clinical trial, resource | Multi-center, placebo-controlled trial of ursodiol in primary sclerosing cholangitis (PSC). A total of 150 patients with previously untreated PSC without cirrhosis were randomly assigned to receive high doses of ursodiol (20-25 mg/kg/day) or placebo for two years. Patients underwent medical evaluation, endoscopic retrograde cholangiography, and liver biopsy before randomization and again at two-year intervals. The endpoints of therapy were progression of hepatic fibrosis, liver decompensation, liver transplantation, or death. The treatment phase of the study was stopped for futility in June 2008; however, patients continue to be followed. Ongoing mechanistic studies are underway. | treatment, placebo, ursodeoxycholic acid, intervention, randomized, adult human, male, female |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: ClinicalTrials.gov |
Primary Sclerosing Cholangitis | NIDDK | PMID:19585548 | nlx_152836 | SCR_006772 | Trial of High-dose Urso in Primary Sclerosing Cholangitis, High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (HUSC), Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis | 2026-02-12 09:44:24 | 0 | |||||
|
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit Resource Report Resource Website |
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit (RRID:SCR_006806) | GLND | clinical trial, resource | Multi-center, double-blind, placebo-controlled, intent-to-treat Phase III trial, designed to determine the effect of parenteral glutamine (GLN) dipeptide on important clinical outcomes in patients requiring surgical intensive care unit (SICU) care and parenteral nutrition (PN) after cardiac, vascular, or intestinal surgery. Patients who required PN and SICU care will receive either standard glutamine (GLN)-free PN (STD-PN) or isocaloric, isonitrogenous alanyl-glutamine dipeptide (AG)-PN until enteral feedings are established. The study will determine whether AG-PN decreases hospital mortality, nosocomial infection and other important indices of morbidity and will obtain mechanistically relevant observational data in the subjects on whether AG-PN a) increases serial blood concentrations of glutathione (GSH), heat shock proteins (HSP)-70 and -27, and glutamine; b) decreases the serum presence of the bacterial products flagellin and lipopolysaccharide (LPS) and the adaptive immune response to these mediators; and c) improves key indices of innate and adaptive immunity. | parenteral nutrition, glutamine, glutamine dipeptide, clinical, outcome, adult human, mortality, nosocomial infection, immune cell function, hospital morbidity, morbidity, intensive care |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: Emory University; Georgia; USA |
Critical illness | NIDDK U01DK069322 | PMID:18596310 | nlx_152823 | http://www.sph.emory.edu/GLND | SCR_006806 | Phase III Study on the Efficacy of Glutamine Dipeptide-Supplemented Parenteral Nutrition in Surgical ICU Patients, Efficacy and Mechanisms of GLN Dipeptide in the SICU, Efficacy and Mechanisms of GLN Dipeptide in the SICU (GLND), GLND trial | 2026-02-12 09:44:24 | 0 | ||||
|
Frequent Hemodialysis Network Nocturnal Trial Resource Report Resource Website |
Frequent Hemodialysis Network Nocturnal Trial (RRID:SCR_007014) | FHN Nocturnal Trial | clinical trial, resource | Randomized controlled clinical trial where subjects will be randomized to conventional hemodialysis delivered three days per week home arm or to the six times per week nocturnal home hemodialysis arm which will follow any dialysis prescription provided their prescribed standardized Kt/V is at least 4.0 and treatment time is at least 6.0 hours, six times per week. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 12 months. Primary Outcome Measures: * composite of 12 month mortality and the change over 12 months in left ventricular mass by cine-MRI, * a composite of 12 month mortality and the change over 12 months in the SF-36 RAND physical health composite Secondary Outcome Measures: * cardiovascular structure/funct (change in LV mass over 12 mos), health-related QoL/phys funct (change over 12 mos in PHC), * depression / dis burden (change over 12 mos in Beck Depression Inv.), nutrition (change over 12 mos in serum albumin, cognitive funct (change over 12 mos in TrailMaking Test B), mineral metabolism (change over 12 mos in aveg pre-dialysis serum phosphorus), * clin events (rate of non-access hospital or death * hypertension, anemia | hemodialysis, home, adult human, kidney, kidney disease |
is listed by: ClinicalTrials.gov is related to: Frequent Hemodialysis Network Daily Trial is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
End Stage Renal Disease, Hemodialysis | NIDDK | PMID:21775973 PMID:17164834 PMID:17699439 |
nlx_152829 | SCR_007014 | Frequent Hemodialysis Network (FHN) Nocturnal Trial, Frequent Hemodialysis Network: Nocturnal Trial | 2026-02-12 09:44:29 | 0 | |||||
|
Program to Reduce Incontinence by Diet and Exercise Resource Report Resource Website 5000+ mentions |
Program to Reduce Incontinence by Diet and Exercise (RRID:SCR_009018) | PRIDE | clinical trial, resource | Randomized controlled trial being conducted at two clinical centers in the United States to learn more about the effects of weight loss on urinary incontinence. About 330 overweight women aged 30 or older will participate and will be followed for 18 months. Efficacy of weight reduction as a treatment for urinary incontinence will be examined at 6 months following the intensive weight control program, and the sustained impact of the intervention will be examined at 18 months. To increase the maintenance of weight reduction and facilitate evaluation of the enduring impact of weight loss on urinary incontinence, they propose to study a motivation-based weight maintenance program. At the end of the intensive weight control program, women randomized to the weight loss program will be randomized to either a 12-month skill-based maintenance intervention or to a motivation-based maintenance intervention. The maintenance interventions maximize the potential for sustained weight loss and will allow them to determine if long-term weight reduction will produce continued improvement in urinary incontinence. | female, adult human, weight reduction, intervention, behavior, diet, exercise, motivation, weight maintenance |
is listed by: ClinicalTrials.gov is related to: NIDDK Information Network (dkNET) has parent organization: University of California at San Francisco; California; USA |
Urinary incontinence, Obesity, Weight loss, Overweight, Aging | NIDDK UO1 DK67860 | PMID:20664387 PMID:20680012 PMID:19179316 PMID:20643425 |
nlx_152847 | SCR_009018 | PRIDE (Program to Reduce Incontinence by Diet and Exercise) | 2026-02-12 09:44:46 | 6544 | |||||
|
ACCORD Resource Report Resource Website 100+ mentions |
ACCORD (RRID:SCR_009015) | ACCORD | clinical trial, resource | Study testing whether strict glucose control lowers the risk of heart disease and stroke in adults with type 2 diabetes. In addition the study is exploring: 1) Whether in the context of good glycemic control the use of different lowering lipid drugs will further improve these outcomes and 2) If strict control of blood pressure will also have additional beneficial effects on reducing cardiovascular disease. The design was a randomized, multicenter, double 2 X 2 factorial trial in 10,251 patients with type 2 diabetes mellitus. It was designed to test the effects on major CVD events of intensive glycemia control, of fibrate treatment to increase HDL-cholesterol and lower triglycerides (in the context of good LDL-C and glycemia control), and of intensive blood pressure control (in the context of good glycemia control), each compared to an appropriate control. All 10,251 participants were in an overarching glycemia trial. In addition, one 2 X 2 trial addressed the lipid question in 5,518 of the participants and the other 2 X 2 trial addressed the blood pressure question in 4,733 of the participants. The glycemia trial was terminated early due to higher mortality in the intensive compared with the standard glycemia treatment strategies. The results were published in June 2008 (N Eng J Med 2008;358:2545-59). Study-delivered treatment for all ACCORD participants was stopped on June 30, 2009, and the participants were assisted as needed in transferring their care to a personal physician. The lipid and blood pressure results (as well as the microvascular outcomes and eye substudy results) were published in 2010. All participants are continuing to be followed in a non-treatment observational study. | middle adult human, late adult human, glycemic control, lowering lipid drug, blood pressure, lipid, clinical |
is related to: NIDDK Information Network (dkNET) has parent organization: National Heart Lung and Blood Institute |
Cardiovascular disease, Stroke, Type 2 diabetes, Diabetes, Aging | NHLBI ; NIDDK ; NEI ; CDC ; NIA |
PMID:23490598 PMID:23253271 PMID:23238658 PMID:22723583 PMID:22646230 |
nlx_152746 | SCR_009015 | Action to Control Cardiovascular Disease Risk in Diabetes | 2026-02-12 09:44:55 | 173 | |||||
|
Pancreatlas Resource Report Resource Website 10+ mentions |
Pancreatlas (RRID:SCR_018567) | data or information resource, atlas | Collection of human pancreas data and images. Platform to share data from human pancreas samples. Houses reference datasets from human pancreas samples, achieved through generosity of organ donors and their families. | Human pancreas data, pancreas image, reference dataset, human pancreas sample, organ donor pancreas data |
lists: Exeter Archival Diabetes Biobank (EADB) is related to: Vanderbilt University; Tennessee; USA is related to: Human Islet Research Network (HIRN) works with: Exeter Archival Diabetes Biobank (EADB) |
Type 1 diabetes, Diabetes, Type 2 diabetes, Cystic Fibrosis-Related Diabetes | Leona M. and Harry B. Helmsley Charitable Trust ; NIDDK DK104211; NIDDK DK108120; NIDDK DK112232; NIDDK DK106755; NIDDK DK20593; NCI CA68485; NIDDK DK58404; NIDDK DK59637; NEI EY08126 |
Free, Freely available | SCR_018567 | 2026-02-12 09:47:34 | 10 | ||||||||
|
White Adipose Atlas Resource Report Resource Website 1+ mentions |
White Adipose Atlas (RRID:SCR_023625) | data or information resource, atlas | Single cell atlas of human and mouse white adipose tissue. | white adipose tissue, adipose tissue, human, mouse | NIDDK RC2 DK116691; NIDDK 5P30 DK057521; NIDDK F32 DK124914; Italian Ministry of University ; Novo Nordisk Foundation ; Lundbeck Foundation ; NIDDK UM1 DK126185; Sarnoff Cardiovascular Research Foundation Fellowship ; NHGRI 1K08 HG010155; NHGRI 1U01 HG011719; NIDDK P30 DK046200 |
PMID:35296864 | Free, Freely available | SCR_023625 | 2026-02-12 09:48:02 | 5 | |||||||||
|
National Glycohemoglobin Standardization Program Resource Report Resource Website 500+ mentions |
National Glycohemoglobin Standardization Program (RRID:SCR_015885) | NGSP | data or information resource, portal, project portal | Project that aims to standardize Hemoglobin A1c test results to those of the Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS) which established the direct relationships between HbA1c levels and outcome risks in patients with diabetes. | glycohemoglobin, diabetes, dcct, ukpds, hba1c, diabetes patient, hemoglobin, a1c |
is listed by: NIDDK Information Network (dkNET) is listed by: Diabetes Research Centers |
Diabetes | NIDDK UC4 DK096587 | Public | SCR_015885 | NGSP: National Glycohemoglobin Standardization Program | 2026-02-12 09:46:39 | 922 | ||||||
|
Type 1 Diabetes Resource Resource Report Resource Website 1+ mentions |
Type 1 Diabetes Resource (RRID:SCR_001475) | T1DR | biomaterial supply resource, organism supplier, material resource | International repository for importation, curation, genotypic and phenotypic validation, cryopreservation, and distribution of mouse stocks of value to the type 1 diabetes scientific community holding over 250 genetically modified or congenic mouse stocks that are being used to dissect genetic and biologic features of T1D. They provide extensive genotypic and phenotypic quality control and genetic stabilization for these strains, as well as incidence studies when available. An added value of T1DR stocks is their ability to propel advances in related areas of science, including research in non-T1D autoimmunity and infectious diseases. The staff provides information and technical assistance regarding selection and use of existing T1DR models, and will provide limited support for development of new models considered to be of high-value for the T1D community. The resource includes strains generated at the Jackson Laboratory as well as strains donated by external scientists. Investigators are highly encouraged to donate a strain to ensure its preservation and availability to other researchers. | genotype, phenotype, animal model |
is listed by: One Mind Biospecimen Bank Listing is listed by: NIDDK Information Network (dkNET) has parent organization: Jackson Laboratory |
Type 1 diabetes, Diabetes | NIDDK UC4DK097610 | Free, Freely Available | nlx_152730 | SCR_001475 | 2026-02-13 10:54:51 | 1 | ||||||
|
Type 1 Diabetes TrialNet Resource Report Resource Website 10+ mentions |
Type 1 Diabetes TrialNet (RRID:SCR_001508) | TrialNet | portal, clinical trial, resource, data or information resource, disease-related portal, database, topical portal | International network of researchers who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes. It is conducting clinical trials with researchers from 18 Clinical Centers in the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia and New Zealand. In addition, more than 150 medical centers and physician offices are participating in the TrialNet network. Studies are available for people newly diagnosed with type 1 diabetes, as well as for relatives of people with type 1 diabetes who are at greater risk of developing the disease. This NIH-sponsored clinical trials network conducts studies designed to evaluate new approaches to prevent or ameliorate type 1 diabetes specifically by interdicting the type 1 diabetes disease process. These include interventions designed to decrease beta-cell destruction and/or enhance beta-cell survival. Studies are conducted in non-diabetic persons at risk of type 1 diabetes in an effort to delay the development of type 1 diabetes as a clinical disease; or (if initiated prior to appearance of autoimmunity) in an effort to delay the appearance of autoimmunity; or in individuals with type 1 diabetes who are either newly diagnosed or have evidence of sustained beta cell function. Studies include long-term follow-up of subjects developing type 1 diabetes. The TrialNet network also supports natural history and genetics studies in populations screened for or enrolled in studies conducted by the TrialNet study group. In addition, TrialNet will evaluate methodologies that enhance the conduct of clinical trials interdicting the type 1 diabetes disease process. | intervention, beta-cell, clinical, child, young human, natural history, genetics, prevention, delay |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository has parent organization: University of South Florida; Florida; USA is parent organization of: Living Biobank |
Diabetes, Type 1 diabetes | NIDDK U01DK061058 | Available to the research community | nlx_152812 | SCR_001508 | 2026-02-13 10:54:52 | 22 | ||||||
|
CKID A Prospective Cohort Study of Kidney Disease in Children Resource Report Resource Website 10+ mentions |
CKID A Prospective Cohort Study of Kidney Disease in Children (RRID:SCR_001500) | CKID | bibliography, portal, resource, data or information resource, research forum portal, disease-related portal, topical portal | Prospective, observational cohort study of children with mild to moderate chronic kidney disease (CKD) to: (1) determine risk factors for progression of pediatric chronic kidney disease (CKD); (2) examine the impact of CKD on neurocognitive development; (3) examine the impact of CKD on risk factors for cardiovascular disease, and; (4) examine the impact of CKD on growth. The CKiD study population will include a cohort of 540 children, age 1 16 years, expected to be enrolled over a 24-month period. | child, young human, pediatric, risk factor, kidney function, neurodevelopment, cognitive ability, behavior, kidney, urologic problem, glomerular disease, adverse effect, cognition, growth, adolescent, infant, clinical |
is listed by: NIDDK Information Network (dkNET) has parent organization: Johns Hopkins University; Maryland; USA |
Chronic kidney disease, Renal disease, Cardiovascular disease | NIDDK U01DK066174; NCRR M01RR000052 |
Free, Freely available | nlx_152790 | SCR_001500 | CKID: A Prospective Cohort Study of Kidney Disease in Children, Chronic Kidney Disease in Children | 2026-02-13 10:54:51 | 10 | |||||
|
Collaborative Islet Transplant Registry Resource Report Resource Website 1+ mentions |
Collaborative Islet Transplant Registry (RRID:SCR_001466) | CITR | data repository, storage service resource, resource, data or information resource, service resource, report, narrative resource, database | Collect, analyze, and communicate on comprehensive and current data on all islet/beta cell transplants in human recipients performed in North America, as well as some European and Australian centers to expedite progress and promote safety in islet/beta cell transplantation. This site serves as a repository for general information concerning protocols, clinical transplantation sites, publications, and other information of interest to the general community. Annual Reports are available. Islet/beta cell transplantation is a complex procedure with many factors contributing to the outcome. Compiling and analyzing data from all transplant centers in the US, Canada, as well as some European and Australian centers will accelerate the identification of both critical risk factors and key determinants of success and thereby guide transplant centers in developing and refining islet/beta cell transplant protocols. The inclusion of the term collaborative in the name of the Registry emphasizes the importance of collaboration in fulfilling the CITR mission and goals. Close collaboration with the transplant centers will ensure that relevant questions are addressed, that data submitted are accurate and complete, and that the needs of the transplant community are served. Information on how to participate as a CITR Transplant Center and to receive a transplant center application is available through the website. Progress in islet transplantation depends entirely on complete, high-quality medical data, including the information patients consented to report to the Collaborative Islet Transplant Registry. To make it as easy as possible to provide updated information about patient's health, an on-line questionnaire is available or patients can mail it to their transplant center. This information is very important in the continuing search for a cure for Type 1 diabetes. | transplant center, transplant, islet, beta cell, clinical, islet transplantation, beta cell transplantation, outcome, metadata standard, adverse event report, diabetes, data element, bibliography, questionnaire, protocol, risk factor, case report form, allograft, pancreatectomy, autograft, islet processing | is listed by: NIDDK Information Network (dkNET) | Type 1 diabetes, Diabetes | NIDDK N01-DK6-2868; NIDDK N01-DK1-2472 |
PMID:15387102 | Free, Freely Available | nlx_152693 | SCR_001466 | 2026-02-13 10:54:52 | 9 | |||||
|
Teen-Longitudinal Assessment of Bariatric Surgery Resource Report Resource Website |
Teen-Longitudinal Assessment of Bariatric Surgery (RRID:SCR_001492) | data or information resource, organization portal, portal, consortium | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on June 29,2023. Consortium made up of five clinical centers and a data coordinating center. The goal of Teen-LABS is to conduct clinical, epidemiological, and behavioral research in adolescent bariatric surgery, through an observational prospective study protocol. Teen-LABS is an ancillary study to LABS, an observational study of adult bariatric surgery. Research staff, certified in standardized uniform data collection according to the protocol, collect data at pre-operative research visits, at surgery, 30 days and six months post-operative, and annual post-operative research visits at the five participating centers. | adolescent human, bariatrics, pre-operative, at surgery, post-operative, clinical, epidemiology, behavior, surgical outcome, metadata standard, observational study, clinical, experimental protocol, evidence-based recommendation, patient evaluation, follow-up care | is listed by: NIDDK Information Network (dkNET) | Bariatric surgery, Obesity | NIDDK R01DK080020 | THIS RESOURCE IS NO LONGER IN SERVICE | SCR_014388, nlx_152747 | SCR_001492 | Teen-LABS, Adolescent Bariatrics: Assessing Health Benefits and Risks, Teen-Longitudinal Assessment of Bariatric Surgery, Adolescent Bariatrics: Assessing Health Benefits and Risks (Teen-LABS) | 2026-02-13 10:54:51 | 0 | ||||||
|
Globin Gene Server Resource Report Resource Website 10+ mentions |
Globin Gene Server (RRID:SCR_001480) | Globin Gene Server | data analysis service, analysis service resource, resource, data or information resource, production service resource, source code, service resource, software resource, narrative resource, training material, database | Data and tools for studying the function of DNA sequences, with an emphasis on those involved in the production of hemoglobin. It includes information about naturally-occurring human hemoglobin mutations and their effects, experimental data related to the regulation of the beta-like globin gene cluster, and software tools for comparing sequences with one another to discover regions that are likely to play significant roles. | dna sequence, hemoglobin, mutation, globin gene cluster, sequence comparison, functional genomics, gene, alignment, genetic analysis, variant, gene expression, protein, thalassemia, globin gene, genome, pairwise alignment, multiple alignment, annotation, sequence analysis, dna |
is listed by: NIDDK Information Network (dkNET) has parent organization: Pennsylvania State University |
NLM R01LM05773; NLM R01LM05110; NIDDK DK27635 |
PMID:11857738 PMID:11480780 PMID:9799599 PMID:9576329 PMID:8088828 |
Free, Freely available | nlx_152723 | SCR_001480 | 2026-02-13 10:54:52 | 27 | ||||||
|
Pediatric Acute Liver Failure Study Resource Report Resource Website |
Pediatric Acute Liver Failure Study (RRID:SCR_001478) | PALF | portal, resource, data or information resource, research forum portal, disease-related portal, topical portal | Study group and network for a 2008 longitudinal study for the etiology, diagnosis, treatment, and outcome of acute liver failure in infants, children, and adolescents. Data from patients include urine, bile, serum, liver tissue, cell lines derived from fibroblast culture, and DNA. | management strategy, infant, child, adolescent, clinical, liver, patient care, rare disease, blood, tissue, longitudinal, urine, bile, serum, liver tissue, cell line, fibroblast culture, dna, etiology, diagnosis, treatment, outcome |
is listed by: NIDDK Information Network (dkNET) is related to: Acute Liver Failure Study Group has parent organization: University of Pittsburgh; Pennsylvania; USA |
Acute liver failure | NIDDK U01DK072146 | Free, Freely available | nlx_152715 | http://www.palfstudy.org/ | SCR_001478 | Pediatric Acute Liver Failure (PALF) Study, Pediatric Acute Liver Failure (PALF) Study Group | 2026-02-13 10:54:51 | 0 | ||||
|
Type 1 Diabetes Genetics Consortium Resource Report Resource Website 1+ mentions |
Type 1 Diabetes Genetics Consortium (RRID:SCR_001557) | T1DGC | portal, resource, data or information resource, research forum portal, disease-related portal, topical portal | Data and biological samples were collected by this consortium organizing international efforts to identify genes that determine an individual risk of type 1 diabetes. It originally focused on recruiting families with at least two siblings (brothers and/or sisters) who have type 1 diabetes (affected sibling pair or ASP families). The T1DGC completed enrollment for these families in August 2009. They completed enrollment of trios (father, mother, and a child with type 1 diabetes), as well as cases (people with type 1 diabetes) and controls (people with no history of type 1 diabetes) from populations with a low prevalence of this disease in January 2010. T1DGC Data and Samples: Phenotypic and genotypic data as well as biological samples (DNA, serum and plasma) for T1DGC participants have been deposited in the NIDDKCentral Repositories for future research. | gene, genetics, genotyping, analytic, dna, serum, plasma, data set, biomaterial supply resource, phenotypic, genotypic, autoantibody, hla, phenotype, genotype |
is listed by: One Mind Biospecimen Bank Listing is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository |
Type 1 diabetes, Diabetes | NIDDK ; NIAID ; NHGRI ; JDRF |
PMID:17130525 | Free, Freely available | nlx_152867 | SCR_001557 | Type 1 Diabetes Genetics Consortium (T1DGC) | 2026-02-13 10:54:53 | 2 | ||||
|
Intestinal Stem Cell Consortium Resource Report Resource Website 10+ mentions |
Intestinal Stem Cell Consortium (RRID:SCR_001555) | ISCC | data or information resource, organization portal, portal, consortium | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 23,2022. Consortium to advance the understanding of intestinal epithelial stem cell biology during development, homeostasis, regeneration and disease. Its immediate goals are to isolate, characterize, culture and validate populations of intestinal stem cells; answer major questions in stem cell biology of the intestinal epithelium; and accelerate research by making information and resources available to the research community. Resources include data sets, protocols, and a resource catalog. Long-term goals include: 1) laying the ground work for therapeutic manipulation of the intestinal epithelium 2) contributing to the greater understanding of stem cell biology through knowledge of the intestine as a model stem cell-driven system. Research Projects are housed at 8 institutions across the nation: Oregon Health & Science University, Stanford University, Stowers Institute for Medical Research, University of California, Los Angeles School of Medicine (UCLA) (partnered with the VA Greater Los Angeles), University of North Carolina, Chapel Hill (UNC), University of Oklahoma, University of Pennsylvania, and University of Pittsburgh. | intestinal, epithelial stem cell, development, homeostasis, regeneration, disease, intestine, stem cell, intestinal stem cell, intestinal epithelium, stem cell, antibody, epithelium, data set |
is used by: NIF Data Federation is used by: NIDDK Information Network (dkNET) is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources |
NIDDK U01DK085532 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152862 | SCR_001555 | ISCC - Intestinal Stem Cell Consortium | 2026-02-13 10:54:52 | 19 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the nidm-terms Resources search. From here you can search through a compilation of resources used by nidm-terms and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that nidm-terms has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on nidm-terms then you can log in from here to get additional features in nidm-terms such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into nidm-terms you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
